当前位置:
X-MOL 学术
›
JAMA Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Radiation Therapy Followed by Intrathecal Trastuzumab-Pertuzumab for ERBB2-Positive Breast Leptomeningeal Disease
JAMA Oncology ( IF 22.5 ) Pub Date : 2024-05-23 , DOI: 10.1001/jamaoncol.2024.1299 Kamran A. Ahmed 1 , Priya U. Kumthekar 2 , Yolanda Pina 3 , Youngchul Kim 4 , Michael A. Vogelbaum 3 , Hyo S. Han 5 , Peter A. Forsyth 3, 6
JAMA Oncology ( IF 22.5 ) Pub Date : 2024-05-23 , DOI: 10.1001/jamaoncol.2024.1299 Kamran A. Ahmed 1 , Priya U. Kumthekar 2 , Yolanda Pina 3 , Youngchul Kim 4 , Michael A. Vogelbaum 3 , Hyo S. Han 5 , Peter A. Forsyth 3, 6
Affiliation
This nonrandomized controlled trial examines the safety of radiation therapy (RT) followed by intrathecal trastuzumab and pertuzumab for patients with ERBB2-positive breast leptomeningeal disease (LMD).
中文翻译:
放射治疗随后鞘内注射曲妥珠单抗-帕妥珠单抗治疗 ERBB2 阳性乳腺软脑膜疾病
这项非随机对照试验检查了放射治疗 (RT) 随后鞘内注射曲妥珠单抗和帕妥珠单抗对于 ERBB2 阳性乳腺软脑膜疾病 (LMD) 患者的安全性。
更新日期:2024-05-23
中文翻译:
![](https://static.x-mol.com/jcss/images/paperTranslation.png)
放射治疗随后鞘内注射曲妥珠单抗-帕妥珠单抗治疗 ERBB2 阳性乳腺软脑膜疾病
这项非随机对照试验检查了放射治疗 (RT) 随后鞘内注射曲妥珠单抗和帕妥珠单抗对于 ERBB2 阳性乳腺软脑膜疾病 (LMD) 患者的安全性。